Orlowski, R.Z. Gercheva, L. Williams, C. Sutherland, H. Robak, T. Masszi, T. Goranova-Marinova, V. Dimopoulos, M.A. Cavenagh, J.D. Špička, I. Maiolino, A. Suvorov, A. Bladé, J. Samoylova, O. Puchalski, T.A. Reddy, M. Bandekar, R. van de Velde, H. Xie, H. Rossi, J.-F., A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma, American Journal of Hematology, (90), 42-49, 2015, Wiley-Liss, Inc., 0361-8609, 1096-8652